Femasys Inc
FEMY Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$1.37
KIRA · Stoqly’s AI analyst, in plain words
- Femasys Inc had $2.3M of revenue in fiscal 2025, up 40.8% on the year before. Over five years, revenue changed +17.2% a year on average.
- Its operating margin was −767.0%, up 324.8 pts: of every 100 in sales, about −767 is left after running the business.
- Femasys Inc lost $18.6M in fiscal 2025.
- Free cash flow was −$19.2M in fiscal 2025, −837.9% of revenue.
Market cap
$4.6M
P/E
0.9x
Revenue
$2.3M
Net income
−$18.6M
Free cash flow
−$19.2M
Operating margin
−767.0%
Femasys Inc in 30 seconds · fiscal 2025
Are sales growing?
+40.8%
Yes. Sales grew 40.8% last year.
Does it make a profit?
−812.3%
No. It lost money last year.
Does profit turn into cash?
−837.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
0.9x
One share costs 0.9 times its yearly profit per share.
What Femasys Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- FEMASYS INC
- CIK
- 0001339005
Femasys Inc · FEMY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Revenue growth | 13.7% | 2.2% | −11.1% | 52.0% | 40.8% |
| Gross margin | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Operating margin | −706.7% | −961.7% | −1,353.4% | −1,091.8% | −767.0% |
| Net income | −$7.5M | −$11.4M | −$14.2M | −$18.8M | −$18.6M |
| Net margin | −639.0% | −944.6% | −1,329.0% | −1,155.0% | −812.3% |
| Diluted EPS | −$1.12 | −$0.96 | −$0.93 | −$0.85 | −$0.47 |
| Cash | |||||
| Cash from operations | −$7.9M | −$10.7M | −$11.3M | −$19.4M | −$18.7M |
| Capital expenditure | $0.3M | $0.4M | $0.1M | $0.8M | $0.5M |
| Free cash flow | −$8.2M | −$11.1M | −$11.4M | −$20.2M | −$19.2M |
| FCF margin | −698.3% | −923.5% | −1,065.7% | −1,240.3% | −837.9% |
| Share buybacks | — | $0.0M | $0.2M | $0.1M | — |
| Share count change | 599.2% | 76.0% | 30.2% | 44.7% | 77.6% |
| Debt and strength | |||||
| Cash and short-term investments | $24.8M | $13.0M | $21.7M | $3.5M | $9.3M |
| Shareholders' equity | $26.3M | $15.2M | $18.4M | $2.3M | $5.9M |
| Current ratio | 15.1x | 9.2x | 7.6x | 0.9x | 4.5x |
| Interest coverage | −434.2x | −859.3x | −87.7x | −11.1x | −9.3x |
| Returns and quality | |||||
| Return on equity | — | −54.8% | −84.8% | −182.2% | −455.8% |
| Return on tangible equity | −28.7% | −74.8% | −77.6% | −840.6% | −324.8% |
| Piotroski F-score | 2 | 2 | 3 | 2 | 2 |
| Altman Z'' | 6.4 | −8.2 | −9.4 | −43.0 | −24.2 |
Insiders bought, 12 months
$0.1M
5 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Femasys Inc · FEMY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.37 a share, the company is worth $4.6M: 0.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001339005). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.